Recruiting Atopic Dermatitis Studies in Lancaster
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this st...
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermat...
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo....
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo....
Shortened Course Adjuvant Radiotherapy Following TORS
This is a single-arm, phase II study to establish the safety of reducing radiation dose in selected HPV-Associated OPSCC patients receiving adjuvant radiation after TORS and neck dissection. This prot...
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with ...
About Atopic Dermatitis Clinical Trials in Lancaster
Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.
There are currently 6 atopic dermatitis clinical trials recruiting participants in Lancaster, SOUTH%20CAROLINA. These studies are seeking a combined 2,503 participants. Research is being sponsored by Sanofi, Eli Lilly and Company, Bluefin Biomedicine, Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Atopic Dermatitis Clinical Trials in Lancaster — FAQ
Are there atopic dermatitis clinical trials in Lancaster?
Yes, there are 6 atopic dermatitis clinical trials currently recruiting in Lancaster, SOUTH%20CAROLINA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lancaster?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lancaster research site will contact you about next steps.
Are clinical trials in Lancaster free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lancaster studies also compensate for your time and travel.
What atopic dermatitis treatments are being tested?
The 6 active trials in Lancaster are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.
Data updated March 2, 2026 from ClinicalTrials.gov